{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:51:24Z","timestamp":1788504684162,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11102-025-01594-1","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:19:34Z","timestamp":1761153574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study"],"prefix":"10.1007","volume":"28","author":[{"given":"Irit","family":"Ayalon-Dangur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzipora","family":"Shochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Kushnir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Rudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idit","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-344X","authenticated-orcid":false,"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"4","key":"1594_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G, Prolactin (2000) Structure, Function, and regulation of secretion. Physiol Rev 80(4):1523\u20131631. https:\/\/doi.org\/10.1152\/physrev.2000.80.4.1523","journal-title":"Physiol Rev"},{"issue":"12","key":"1594_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of Prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"1594_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00227-X","volume":"13","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S (2025) Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol S221385872500227X. https:\/\/doi.org\/10.1016\/S2213-8587(25)00227-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1594_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1018090","author":"A Glezer","year":"2023","unstructured":"Glezer A, Santana MR, Bronstein MD, Donato J, Jallad RS (2023) The interplay between prolactin and cardiovascular disease. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2022.1018090","journal-title":"Front Endocrinol"},{"issue":"3","key":"1594_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11102-013-0495-z","volume":"17","author":"X-B Jiang","year":"2014","unstructured":"Jiang X-B, Li C-L, He D-S, Mao Z-G, Liu D-H, Fan X, Hu B, Zhu Y-H, Wang H-J (2014) Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 17(3):232\u2013239. https:\/\/doi.org\/10.1007\/s11102-013-0495-z","journal-title":"Pituitary"},{"key":"1594_CR6","doi-asserted-by":"publisher","unstructured":"Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S (2003) Endothelial Function, insulin sensitivity and inflammatory markers in hyperprolactinemic Pre-Menopausal women. Eur J Endocrinol 187\u2013193. https:\/\/doi.org\/10.1530\/eje.0.1490187","DOI":"10.1530\/eje.0.1490187"},{"issue":"5","key":"1594_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4158\/EP13173.OR","volume":"20","author":"MS Arslan","year":"2014","unstructured":"Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T (2014) Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract 20(5):447\u2013451. https:\/\/doi.org\/10.4158\/EP13173.OR","journal-title":"Endocr Pract"},{"issue":"4","key":"1594_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041658","volume":"12","author":"M Arcopinto","year":"2023","unstructured":"Arcopinto M, D\u2019Assante R, Auriemma RS, Pirchio R, Pivonello R, Bossone E, Colao A, Cittadini A (2023) Early left ventricular diastolic dysfunction in females with chronic hyperprolactinemia: a doppler echocardiographic study. JCM 12(4):1658. https:\/\/doi.org\/10.3390\/jcm12041658","journal-title":"JCM"},{"issue":"12","key":"1594_CR9","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.4158\/EP171985.OR","volume":"23","author":"X-B Jiang","year":"2017","unstructured":"Jiang X-B, Zhang J, Li C, Mao Z-G, Hu B, Zhu Z, Zhu Y-H, Wang H-J (2017) Subclinical impairment of left ventricular longitudinal function in patients with prolactinomas. Endocr Pract 23(12):1379\u20131386. https:\/\/doi.org\/10.4158\/EP171985.OR","journal-title":"Endocr Pract"},{"issue":"2","key":"1594_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000362550","volume":"78","author":"ED Ozdemir","year":"2014","unstructured":"Ozdemir ED, Caglar GS, Akgul E, Cengiz SD, Tombak G (2014) The association between prolactin, high-sensitivity c-reactive protein and Framingham risk score in menopause. Gynecol Obstet Invest 78(2):119\u2013123. https:\/\/doi.org\/10.1159\/000362550","journal-title":"Gynecol Obstet Invest"},{"issue":"12","key":"1594_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122203","volume":"8","author":"I Samperi","year":"2019","unstructured":"Samperi I, Lithgow K, Karavitaki N (2019) Hyperprolactinaemia. JCM 8(12):2203. https:\/\/doi.org\/10.3390\/jcm8122203","journal-title":"JCM"},{"issue":"8","key":"1594_CR12","doi-asserted-by":"publisher","first-page":"e1652","DOI":"10.1210\/clinem\/dgae087","volume":"109","author":"AS Papazoglou","year":"2024","unstructured":"Papazoglou AS, Leite AR, Moysidis DV, Anastasiou V, Daios S, Borges-Canha M, Giannopoulos G, Neves JS, Ziakas A, Giannakoulas G (2024) Serum prolactin levels and mortality in adults without prolactinoma: a meta-analysis. J Clin Endocrinol Metab 109(8):e1652\u2013e1664. https:\/\/doi.org\/10.1210\/clinem\/dgae087","journal-title":"J Clin Endocrinol Metab"},{"issue":"06","key":"1594_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0043-107243","volume":"49","author":"J Krogh","year":"2017","unstructured":"Krogh J, Selmer C, Torp-Pedersen C, Gislason G, Kistorp C (2017) Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm Metab Res 49(06):411\u2013417. https:\/\/doi.org\/10.1055\/s-0043-107243","journal-title":"Horm Metab Res"},{"issue":"14","key":"1594_CR14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurjpc\/zwad112","volume":"30","author":"Y Shen","year":"2023","unstructured":"Shen Y, Yang Q, Hu T, Wang Y, Chen L, Gao F, Zhu W, Hu G, Zhou J, Wang C, Bao Y (2023) Association of prolactin with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study. Eur J Prev Cardiol 30(14):1439\u20131447. https:\/\/doi.org\/10.1093\/eurjpc\/zwad112","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"1594_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1530\/ec-17-0171","volume":"6","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Leese GP (2017) Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect 6(8):580\u2013588. https:\/\/doi.org\/10.1530\/ec-17-0171","journal-title":"Endocr Connect"},{"issue":"2","key":"1594_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1594_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13494","volume":"37","author":"A Akirov","year":"2025","unstructured":"Akirov A, Rudman Y, Sharon Y, Shimon I, Kushnir S, Diker-Cohen T (2025) Ischemic stroke risk in patients with dopamine agonist\u2010treated hyperprolactinemia. J Neuroendocrinol 37(4):e13494. https:\/\/doi.org\/10.1111\/jne.13494","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"1594_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40618-024-02492-2","volume":"48","author":"L Dery","year":"2024","unstructured":"Dery L, Shimon I, Rudman Y, Iraqi HM, Kushnir S, Shochat T, Cooper O, Akirov A (2024) Breast cancer risk in patients with dopamine agonist-treated hyperprolactinemia. J Endocrinol Invest 48(3):691\u2013699. https:\/\/doi.org\/10.1007\/s40618-024-02492-2","journal-title":"J Endocrinol Invest"},{"key":"1594_CR19","doi-asserted-by":"publisher","first-page":"1001703","DOI":"10.3389\/fendo.2022.1001703","volume":"13","author":"Y Macotela","year":"2022","unstructured":"Macotela Y, Ruiz-Herrera X, V\u00e1zquez-Carrillo DI, Ram\u00edrez-Hernandez G, de la Mart\u00ednez G, Clapp C (2022) The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne) 13:1001703. https:\/\/doi.org\/10.3389\/fendo.2022.1001703","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1594_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ejendo\/lvaf101","volume":"192","author":"TS Han","year":"2025","unstructured":"Han TS, Hannemann A, Arffman R, Friedrich N, Ittermann T, Wilkening R, Piltonen T, Fry CH, Crujeiras AB, Casanueva FF (2025) The relationship between hypoprolactinemia and cardiometabolic health in women. Eur J Endocrinol 192(5):662\u2013670. https:\/\/doi.org\/10.1093\/ejendo\/lvaf101","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1594_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biom14101335","volume":"14","author":"R Krysiak","year":"2024","unstructured":"Krysiak R, Kowalcze K, Szkr\u00f3bka W, Okopie\u0144 B (2024) Increased cardiometabolic risk in men with hypoprolactinemia: a pilot study. Biomolecules 14(10):1335. https:\/\/doi.org\/10.3390\/biom14101335","journal-title":"Biomolecules"},{"issue":"23","key":"1594_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237088","volume":"13","author":"C Mattiuzzi","year":"2024","unstructured":"Mattiuzzi C, Lippi G (2024) Leading causes of US deaths in the 2022. JCM 13(23):7088. https:\/\/doi.org\/10.3390\/jcm13237088","journal-title":"JCM"},{"issue":"1","key":"1594_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.parkreldis.2014.10.015","volume":"21","author":"V Wang","year":"2015","unstructured":"Wang V, Chao T-H, Hsieh C-C, Lin C-C, Kao C-H (2015) Cancer risks among the users of ergot-derived dopamine agonists for Parkinson\u2019s disease, a nationwide population-based survey. Parkinsonism Relat Disord 21(1):18\u201322. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.10.015","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1594_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/cen.13498","volume":"88","author":"KA Toulis","year":"2018","unstructured":"Toulis KA, Robbins T, Reddy N, Balachandran K, Gokhale K, Wijesinghe H, Cheng KK, Karavitaki N, Wass J, Nirantharakumar K (2018) Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol (Oxf) 88(1):71\u201376. https:\/\/doi.org\/10.1111\/cen.13498","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1594_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-015-0094-4","volume":"7","author":"NA Pala","year":"2015","unstructured":"Pala NA, Laway BA, Misgar RA, Dar RA (2015) Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr 7(1):99. https:\/\/doi.org\/10.1186\/s13098-015-0094-4","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1594_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12020-022-03145-1","volume":"78","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopie\u0144 B (2022) Cardiometabolic profile of young women with hypoprolactinemia. Endocrine 78(1):135\u2013141. https:\/\/doi.org\/10.1007\/s12020-022-03145-1","journal-title":"Endocrine"},{"issue":"6","key":"1594_CR27","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","volume":"15","author":"V Bernard","year":"2019","unstructured":"Bernard V, Young J, Binart N (2019) Prolactin \u2014 a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356\u2013365. https:\/\/doi.org\/10.1038\/s41574-019-0194-6","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1594_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/jim-2022-002351","volume":"70","author":"ZA-S Ghoreshi","year":"2022","unstructured":"Ghoreshi ZA-S, Akbari H, Sharif-zak M, Arefinia N, Abbasi-Jorjandi M, Asadikaram G (2022) Recent findings on hyperprolactinemia and its pathological implications: A literature review. J Investig Med 70(7):1443\u20131451. https:\/\/doi.org\/10.1136\/jim-2022-002351","journal-title":"J Investig Med"},{"issue":"7","key":"1594_CR29","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1097\/HJH.0b013e328339f254","volume":"28","author":"L Zhang","year":"2010","unstructured":"Zhang L, Curhan GC, Forman JP (2010) Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens 28(7):1400\u20131405. https:\/\/doi.org\/10.1097\/HJH.0b013e328339f254","journal-title":"J Hypertens"},{"issue":"2","key":"1594_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s13277-013-0660-z","volume":"34","author":"X-B Jiang","year":"2013","unstructured":"Jiang X-B, He D-S, Mao Z-G, Fan X, Lei N, Hu B, Song B-B, Zhu Y-H, Wang H-J (2013) BMI, apolipoprotein B\/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumor Biol 34(2):1171\u20131176. https:\/\/doi.org\/10.1007\/s13277-013-0660-z","journal-title":"Tumor Biol"},{"key":"1594_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-025-03686-y","author":"M Xu","year":"2025","unstructured":"Xu M, Liu B, Yang A, Luan J, Li S, Zhu L, Shu N, Ouyang G, Wang Y, Wang Y, Ma G (2025) Effects of hyperprolactinemia and Bromocriptine treatment on cerebral blood flow and functional brain States. Neuroradiology. https:\/\/doi.org\/10.1007\/s00234-025-03686-y","journal-title":"Neuroradiology"},{"issue":"4","key":"1594_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1161\/CIRCGENETICS.109.853572","volume":"2","author":"AQ Reuwer","year":"2009","unstructured":"Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJP, Boekholdt SM, Khaw K-T (2009) Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2(4):389\u2013395. https:\/\/doi.org\/10.1161\/CIRCGENETICS.109.853572","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"1594_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11154-024-09927-4","volume":"25","author":"K Coleman","year":"2024","unstructured":"Coleman K, Saleem M (2024) Reference intervals for serum prolactin concentrations: analytical and clinical considerations. Rev Endocr Metab Disord 25(6):995\u20131002. https:\/\/doi.org\/10.1007\/s11154-024-09927-4","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01594-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:47:09Z","timestamp":1765961229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01594-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01594-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Rabin Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}